# Zetagen Therapeutics

> Zetagen Therapeutics is a private, clinical-stage biopharmaceutical company based in Syracuse, New York, developing locally-administered therapies for metastatic and primary cancers that spread to bone. Its lead candidate, ZetaMet (Zeta-BC-003), uses a patented molecular pathway delivered by a single outpatient injection to suspend cancer growth, inhibit pain, and regenerate bone in patients with metastatic breast cancer lytic lesions. Spun out of research at SUNY Upstate Medical University in 2015, the company has earned multiple FDA Breakthrough Designations and reported Phase 2a data showing an 87.9% mean reduction in lesion defect volume.

- **Founded:** 2015
- **Headquarters:** Syracuse, New York, United States
- **Founders:** Bryan Margulies (Co-founder & Chief Scientific Officer), Nikhil Thakur (Co-founder & Chief Medical Officer)
- **Team size:** ~9 employees
- **Products:** ZetaMet (Zeta-BC-003), ZetaMet-P (Zeta-PC-004), ZetaMAST (Zeta-MBC-005), ZetaPrime (Zeta-PBC-007), Zetabase / Zeta Platform
- **Notable:** Multiple FDA Breakthrough Designations for its lead candidate, Phase 2a data showing 87.9% mean reduction in lesion defect volume at day 180 with no skeletal-related events, Composition-of-matter patents granted by the USPTO for its breast cancer platform (2025)

## Products & services

- **ZetaMet (Zeta-BC-003)** — Lead candidate for metastatic breast cancer lytic bone lesions, delivered via a single fluoroscopy-guided intratumoral injection; designed to suspend cancer, inhibit pain, and regenerate bone.
- **ZetaMet-P (Zeta-PC-004)** — Pipeline candidate targeting metastatic prostate cancer bone lesions.
- **ZetaMAST (Zeta-MBC-005)** — Investigational therapy for metastatic breast cancer and soft-tissue lesions.
- **ZetaPrime (Zeta-PBC-007)** — Preclinical candidate advancing through GMP manufacturing and preclinical studies.
- **Zetabase / Zeta Platform** — Proprietary osteoconductive and osteopromotive drug-eluting carrier platform that delivers small-molecule therapy locally while promoting bone regeneration.

## Achievements

- Multiple FDA Breakthrough Designations for its lead candidate
- Phase 2a data showing 87.9% mean reduction in lesion defect volume at day 180 with no skeletal-related events
- Composition-of-matter patents granted by the USPTO for its breast cancer platform (2025)
- Oversubscribed $12.9M Series B1 round closed in November 2025
- Abstract accepted for the 2025 San Antonio Breast Cancer Symposium reporting complete response in MBC bone lesions
- Discovery of a first-of-its-kind molecular pathway to suspend cancer, inhibit pain, and regenerate bone

## Latest updates

- **2025-11** — Closed an oversubscribed $12.9M Series B1 round led by JSTAR Capital Investments to advance ZetaMet toward commercialization.
- **2025-12** — Presented preliminary Phase 2a results at the San Antonio Breast Cancer Symposium, reporting complete response in metastatic breast cancer bone lesions.
- **2025-07** — Secured composition-of-matter patents from the USPTO for its novel breast cancer platform.
- **2025** — Completed enrollment in its Phase 2a clinical study of ZetaMet (Zeta-BC-003) for metastatic breast cancer.

## Links

- Website: https://zetagen.com
- LinkedIn: http://www.linkedin.com/company/zetagen-therapeutics
- Twitter/X: https://twitter.com/ZetaGenTx
- Facebook: https://facebook.com/pages/category/Medical---Health/ZetaGen-Therapeutics-2102529683321846/

---

Profile page: https://yespress.io/zetagen-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-17